

Gastroesophageal Junction Adenocarcinoma Gastric Cancer

**A Study of Atezolizumab and Trastuzumab in Combination With  
Capecitabine and Oxaliplatin in Patients With HER2 Positive  
Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of  
Gastroesophageal Junction**

**Trial Status**  
Active, not recruiting

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT04661150 ML42058

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This is a phase II, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of perioperative trastuzumab+XELOX with / without atezolizumab in participants eligible for surgery with locally advanced HER2-positive gastric cancer or adenocarcinoma of GEJ.

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

**NCT04661150 ML42058**  
Trial Identifiers

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years & ≤ 75 Years

**Healthy Volunteers**  
No